Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaNutra SpAMIL:PHN -1.19%87 EV-to-OCF is 40.35 as of Aug. 17, 2026, which is 20% above its 10-year median of 33.65. GuruFocus rates MIL:PHN with a GF Score™ of 87/100 and a GF Value™ of €72.81 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,005 Drug Manufacturers companies, PharmaNutra SpA ranks worse than 84.78% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PharmaNutra SpA's Enterprise Value is €784.7 Mil.
PharmaNutra SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €19.5 Mil. Therefore, PharmaNutra SpA's EV-to-OCF for today is 40.35.
The historical rank and industry rank for PharmaNutra SpA's EV-to-OCF or its related term are showing as below:
MIL:PHN'
s EV-to-OCF Range Over the Past 10 Years
Min: -859.53 Med: 33.65 Max: 63.19
Current: 40.35
During the past 11 years, the highest EV-to-OCF of PharmaNutra SpA was 63.19. The lowest was -859.53. And the median was 33.65.
MIL:PHN's EV-to-OCF is ranked worse than 84.78% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 11.01
vs MIL:PHN: 40.35
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaNutra SpA's PE Ratio (TTM) for today is calculated as:
PharmaNutra SpA's share price for today is €83.00.
PharmaNutra SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PharmaNutra SpA EV-to-OCF Related Terms
PharmaNutra SpA EV-to-OCF Historical Data
* Premium members only.
The historical data trend for PharmaNutra SpA's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaNutra SpA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaNutra SpA EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaNutra SpA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where PharmaNutra SpA's EV-to-OCF falls into.
PharmaNutra SpA's current Enterprise Value is €784.7 Mil.
PharmaNutra SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaNutra SpA (MIL:PHN) has a EV-to-OCF of 40.35 as of Aug. 17, 2026. This is 20% above median its historical median of 33.65. According to the industry distribution chart, PharmaNutra SpA ranks #852 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 84.8%.
Is PharmaNutra SpA's EV-to-OCF too high?
PharmaNutra SpA's current EV-to-OCF of 40.35 is 20% above median its 10-year median of 33.65. The Drug Manufacturers industry median EV-to-OCF is 11.01. PharmaNutra SpA's value of 40.35 is 266.5% above this industry median. Based on the distribution chart, PharmaNutra SpA ranks #852 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PharmaNutra SpA has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaNutra SpA ranks #852 out of 1005 companies for EV-to-OCF. This places PharmaNutra SpA in the lower half of its industry. The industry median EV-to-OCF is 11.01. PharmaNutra SpA's value of 40.35 is 266.5% above this benchmark. While the company's 10-year median is 33.65 vs. the industry median of 11.01, PharmaNutra SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.01, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current EV-to-OCF of 40.35 is 266.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current EV-to-OCF is 40.35, which is 20% above median its own 10-year median of 33.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (MIL:PHN) is currently considered Modestly Overvalued. The stock's GF Value™ is €72.81, compared to a current price of €83.00 — trading 14% above its estimated fair value. The current EV-to-OCF is 40.35, which is 20% above median its 10-year median of 33.65 and 266.5% above the Drug Manufacturers industry median of 11.01. PharmaNutra SpA's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PharmaNutra SpA (MIL:PHN), the current EV-to-OCF is 40.35 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaNutra SpA (MIL:PHN) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued.
The current stock price of €83.00 is trading 14% above its estimated GF Value™ of €72.81.
GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.
Key valuation signals for MIL:PHN:
EV-to-OCF: 40.35 (20% above median its 10-year median of 33.65)
GF Value™: €72.81 vs. price of €83.00 (14% above fair value)
Industry Position: 266.5% above the Drug Manufacturers median (#852 of 1005)
No single metric tells the full story. See the MIL:PHN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
87GF Score
Get the complete analysis for MIL:PHN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHN has been successfully added to your 
